Global Blood Therapeutics, Inc. GBT
Day range unavailable
52-week range unavailable
- Market cap
- 4.62B
- Revenue (ttm)
- 234.86M
- Profit margin
- -137.30%
- Shares out
- 67.48M
- Forward P/E
- -29.14
- Beta
- 0.46
- Analysts
- Buy
- Price target
- 64.50 (-5.8%)
- Earnings date
- Nov 3, 2022
1Y +33.14 (+93.75%)
Key statistics
- Enterprise value
- 4.76B
- PEG ratio
- -0.44
- Price / sales
- 19.68
- Price / book
- 38.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 50.50%
- Free cash flow
- -134.82M
- Total cash
- 517.16M
- Total debt
- 658.39M
- Return on equity
- -148.56%
- Short % of float
- 11.05%
- 50-day average
- 63.70
- 200-day average
- 38.56
Analyst view
Consensus: buy
- Target (low)
- 60.00
- Target (mean)
- 64.50
- Target (high)
- 68.50
- Strong buy4
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2022
Expected Nov 3, 2022. Consensus EPS estimate -1.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2022 | Sep 1, 2022 | -1.16 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -1.19 | — | — | — |
| May 4, 2022 | Mar 1, 2022 | -1.29 | — | — | — |
| Feb 23, 2022 | Dec 1, 2021 | -1.14 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -1.10 | — | — | — |
| Aug 3, 2021 | Jun 1, 2021 | -1.17 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2022 | RBC Capital | down | Outperform | Sector Perform |
| Aug 9, 2022 | Wells Fargo | down | Overweight | Equal-Weight |
| Aug 9, 2022 | SVB Leerink | down | Outperform | Market Perform |
| Aug 19, 2022 | Cantor Fitzgerald | down | Overweight | Neutral |
| Aug 9, 2022 | Cowen & Co. | down | Outperform | Market Perform |
| Aug 8, 2022 | Stifel | down | Buy | Hold |
About Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gbt.com
News
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 
Earnings Scheduled For August 8, 2022 
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday - Stocks That Hit 52-Week Lows On Monday
Earnings Scheduled For May 4, 2022 - Earnings Scheduled For February 23, 2022
- Earnings Scheduled For November 4, 2021
- Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
- Earnings Scheduled For August 3, 2021
Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on GBT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHOI JUNG E. | Officer | Stock Gift | Sep 28, 2022 | 251,672 |
| FARROW JEFFREY S | Chief Financial Officer | Conversion of Exercise of derivative security | Sep 26, 2022 | 26,739 |
| HABIBIZAD NAZILA | Officer | Conversion of Exercise of derivative security | Sep 26, 2022 | 41,623 |
| JOHNSON DAVID LEE | Chief Operating Officer | Conversion of Exercise of derivative security | Aug 31, 2022 | 56,384 |
| KREHLIK CARRIE | Officer | Conversion of Exercise of derivative security | Aug 31, 2022 | 6,716 |
| LOVE TED WENDELL | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 26, 2022 | 802,968 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 8.92% | 6,019,431 | 412.27M | Jun 29, 2022 |
| Blackrock Inc. | 7.07% | 4,772,391 | 326.86M | Jun 29, 2022 |
| Janus Henderson Group PLC | 6.64% | 4,478,248 | 306.72M | Jun 29, 2022 |
| State Street Corporation | 6.56% | 4,423,544 | 302.97M | Jun 29, 2022 |
| Baker Brothers Advisors, LLC | 5.53% | 3,732,502 | 255.64M | Jun 29, 2022 |
| Deep Track Capital, LP | 5.40% | 3,646,690 | 249.76M | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 4.50% | 3,034,375 | 207.82M | Aug 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.84% | 1,914,662 | 131.14M | Jun 29, 2022 |
| Vanguard Small-Cap Index Fund | 2.43% | 1,637,261 | 112.14M | Jun 29, 2022 |
| iShares Russell 2000 ETF | 2.00% | 1,347,913 | 92.32M | Aug 30, 2022 |
| Janus Henderson Global Life Sciences Fund | 1.53% | 1,030,590 | 70.59M | Jun 29, 2022 |
| Vanguard Small-Cap Growth Index Fund | 1.44% | 969,336 | 66.39M | Jun 29, 2022 |